 Cerus FDA CE approved Intercept pathogen reduction platform for platelets and plasma gathering momentum as FDA Guidelines require compliance with new blood safety measures by March 31, 2021. Cerus plans to file for FDA extension of intercept platelet label from 5 to 7-day shelf life in 2021 should accelerate US-wide adoption of Intercept platelets. 